San Diego immunotherapy company seeks to raise $100,000 to complete IND enabling experiments for the FDA
June 18, 2014
Batu Biologics announced today the launch of its first crowdfunding campaign with Indiegogo seeking to raise $100,000 dollars to complete preclinical testing for Vallovax, an immunotherapeutic product which selectively kills blood vessels feeding the tumor.
Individuals seeking to contribute may do so at: https://www.indiegogo.com/projects/emerging-lung-cancer-vaccine-targets-tumor-blood-vessels-introducing-vallovax
ValloVax™ combats cancer by training the immune system to selectively target the blood vessels of the tumor, or the tumor endothelium, preventing the sustainable growth and proliferation of neoplastic cells.
Batu’s strategy is focused on preparing ValloVax™ to enter Phase I clinical trials. Batu Biologics is targeting lung cancer as the first treatment indication for ValloVax™ with expanded indications to follow.
“Batu Biologics is extremely excited to leverage crowdfunding platforms that make contributions to scientific progress easily accessible and understandable to the community,” commented Samuel C. Wagner, President and CEO of Batu Biologics. “We hope to utilize this crowdfunding campaign as a stepping stone toward larger future campaigns. Batu hopes to not only progress the science behind its anti-angiogenic cancer vaccine, VallovaxTM, but to also capitalize on the non-dilutive investment and support from the surrounding community.”
About Batu Biologics: Batu Biologics is a preclinical biopharmaceutical company focusing on developing and commercializing allogeneic cell therapies in the area of immune modulation. Our products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stages of drug development for its two flagship products: Immstem and Vallovax. Batu Biologics has filed two provisional patents in the field of cancer immunotherapy and plans to significantly expand its IP in 2014. Recently, Batu Biologics published in the peer reviewed literature with Dr. Francesco Marincola, President of the Society for Immunotherapy of Cancer, as well as several other internationally-renowned immunotherapists, a novel method of decreasing toxicity of immunotherapy http://www.translational-medicine.com/content/pdf/1479-5876-12-127.pdf